Turning Point 2011

2010 CoverA selection of articles from the 2011 issue of Turning Point.

To see the entire publication, please download the PDF version. If you'd like to receive a print version of Turning Point in the mail, please complete this form.

  • A new center, an ongoing mission

    How the Susan F. Smith Center for Women's Cancers is building on a legacy of successes.

  • Ask the care team

    Dana-Farber's experts answer questions about breast and ovarian cancer.

  • Blocking the path to cancer growth

    HER2, a growth factor receptor model, is active in a very small number of ovarian cancers, but its genetic cousin, HER3, has been estimated to be abnormal in 25 to 30 percent of ovarian tumors.

  • Seeking genetic culprits in cervical cancer

    Researchers have begun probing the relatively unknown cellular territory of cervical cancer, hunting for new opportunities to block the mutated gene pathways driving the cancer.

  • PARP inhibitors on trial

    The promise and potential limitations of a new class of cancer drugs.

Turning Point is published for supporters of Dana-Farber's Susan F. Smith Center for Women's Cancers. To learn more about the Susan Smith Center and its offerings, call Administrative Director Candace S. Lowe, ScD, at 617-632-2675. 

Comments, suggestions, and requests to be added to or deleted from the mailing list may be sent to:

Turning Point
Dana-Farber Cancer Institute
Department of Communications
450 Brookline Ave.
Boston, MA 02115
Phone: 617-632-4090
Email: TurningPoint@dfci.harvard.edu  

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms
  • Media Contacts

    • For all inquiries, call 617-632-4090 and ask to speak to a member of the media team. Please direct emails to media@dfci.harvard.edu.
     
  • Request a Publication

    • Receive by mail the current issue of a Dana-Farber publication by completing this request form.